Government Plans Immediate Suspension Of Manufacturing Licences For Substandard Drug Producers Nationwide

The Union Government has proposed a <b>strict amendment</b> to the Drugs and Cosmetics Rules, allowing for the <b>immediate suspension</b> of manufacturing licences for companies producing substandard medicines. This move aims to curb the circulation of low-quality drugs that pose severe health risks to the public. Currently, the process to hold pharmaceutical companies accountable for poor quality control is often delayed by lengthy bureaucratic procedures. This new policy mandates that manufacturers must undertake <b>corrective measures</b> before their suspension can be revoked, ensuring that safety is no longer treated as an optional suggestion by profit-driven firms. Will this finally force pharmaceutical giants to prioritize patient safety over their bottom line, or will the paperwork continue to shield the guilty?